Totipotentrx Cell Therapy Profile
Key Indicators
- Authorised Capital ₹ 6.75 Cr
as on 20-12-2024
- Paid Up Capital ₹ 45.02 K
as on 20-12-2024
- Company Age 13 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 2.87%
(FY 2020)
- Profit -26.55%
(FY 2020)
- Ebitda 141.71%
(FY 2020)
- Net Worth -6.69%
(FY 2020)
- Total Assets 5.51%
(FY 2020)
About Totipotentrx Cell Therapy
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.75 Cr and a paid-up capital of Rs 45.02 K , as per Ministry of Corporate Affairs (MCA) records.
Sunny Singh and Xiaochun Xu serve as directors at the Company.
- CIN/LLPIN
U74140HR2011FTC041964
- Company No.
041964
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
28 Jan 2011
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Totipotentrx Cell Therapy?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunny Singh  | Director | 24-Feb-2020 | Current |
Xiaochun Xu  | Director | 02-Jun-2017 | Current |
Financial Performance of Totipotentrx Cell Therapy.
Totipotentrx Cell Therapy Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 2.87% increase. The company also saw a substantial fall in profitability, with a 26.55% decrease in profit. The company's net worth dipped by a decrease of 6.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Totipotentrx Cell Therapy?
In 2019, Totipotentrx Cell Therapy had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Totipotentrx Cell Therapy?
Totipotentrx Cell Therapy has a workforce of 2 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Totipotentrx Cell Therapy, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Totipotentrx Cell Therapy's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
